Methods for administering aripiprazole
View Patent ↗The present invention relates, in part, to the discovery that a pharmaceutical composition comprising aripiprazole and a carrier administered in a bolus injection resulted in an extended release profile similar to that obtained by the injection of a poly lactide-co-glycolide microsphere formulation containing the active agent. This surprising result suggests that pharmacologically beneficial extended release formulations without the complexities and expense associated with the manufacture microspheres.
1. An injectable composition that is free of sustained release matrices for the extended release of aripiprazole comprising a suspension of at least about 10 mg/ml of aripiprazole in an injection vehicle optionally comprising a viscosity enhancing agent wherein the aripiprazole release is for at least 21 days.
2. A method for providing aripiprazole to an individual in an extended release injectable composition that is free of sustained release matrices comprising administering a mixture of at least about 10 mg/ml of aripiprazole in an injection vehicle optionally comprising a viscosity enhancing agent, wherein a therapeutically effective amount of the aripiprazole is present in the plasma of the individual for at least about 21 days.